Literature DB >> 576175

Identification of subgroups of euthyroid graves's ophthalmopathy.

D H Solomon, I J Chopra, U Chopra, F J Smith.   

Abstract

We attempted to determine if euthyroid Graves's ophthalmopathy is a single entity or a heterogeneous group of disorders. Activity of long acting thyroid stimulator protector occurred in 31 of 33 patients with Graves's hyperthyroidism but in only nine of 17 with euthyroid Graves's ophthalmopathy. Of the euthyroid patients, six had protector activity and thyroid non-suppressibility; firm goiters and high titers of thyroid antibodies were the rule in this group. We believe that these patients have three autoimmune diseases: Hashimoto's thyroiditis, Graves's thyroid disease and Graves's ophthalmopathy. Five euthyroid patients had no detectable protector activity or thyroid antibodies and had normal thyroid suppressibility; the thyroid was generally normal in size and consistence. These patients are interpreted as having "isolated" Graves's ophthalmopathy without any autoimmune thyroid disease. The remaining six patients showed dissociation between protector activity and thyroid non-suppressibility and cannot be classified as yet. Euthyroidism in Graves's ophthalmopathy may have more than one cause.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 576175     DOI: 10.1056/NEJM197701272960401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  29 in total

1.  T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy.

Authors:  A Pappa; J M Lawson; V Calder; P Fells; S Lightman
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

2.  Concomitant euthyroid Graves' ophthalmopathy and isolated ocular myasthenia gravis.

Authors:  H Raef; M Ladinsky; R Arem
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

3.  Response to TRH, serum thyroid hormone concentration, and serum markers of autoimmunity after antithyroid therapy in Graves' disease.

Authors:  B A Lamberg; A Aro; P Saarinen; T Tötterman; T Mäkinen
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

4.  Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves' disease. A reliable indicator for remission and persistence of this disease?

Authors:  H Schleusener; R Finke; P Kotulla; K W Wenzel; H Meinhold; H D Roedler
Journal:  J Endocrinol Invest       Date:  1978-04       Impact factor: 4.256

5.  Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.

Authors:  J Ginsberg; C von Westarp
Journal:  CMAJ       Date:  1986-05-15       Impact factor: 8.262

6.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

7.  The pathogenesis and treatment of Graves' ophthalmopathy.

Authors:  I R Jones
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

8.  The effect of subtotal thyroidectomy on Graves' ophthalmopathy.

Authors:  M D Levitt; A J Edis; R Agnello; C C McCormick
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

9.  A specific IgG in Graves' ophthalmopathy and its relation to retro-orbital and thyroid autoimmunity.

Authors:  P Kendall-Taylor; S Atkinson; M Holcombe
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-21

10.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.